Can Wegovy Cause Gastroparesis or Stomach Paralysis?

Semaglutide, the active ingredient in Wegovy and Ozempic, slows down how fast your stomach empties food, and in a small but real number of users, this effect crosses the line into gastroparesis, sometimes called stomach paralysis. The drug does this by design: delaying gastric emptying is part of how it suppresses appetite and controls blood sugar. But that same mechanism can, in some people, slow the stomach to the point where food sits there far longer than it should, causing persistent nausea, vomiting, bloating, and abdominal pain. The question is not really whether it can happen but how often, how serious it gets, and what makes some people more vulnerable than others.

How GLP-1 Drugs Slow Your Stomach

Semaglutide belongs to a class of drugs called GLP-1 receptor agonists, which mimic a natural hormone your gut releases after eating. One of the places those receptors sit is in a part of the brainstem called the nucleus of the solitary tract, a cluster of neurons that helps regulate how your stomach contracts and moves food along.¹ When semaglutide activates those receptors, the stomach’s normal rhythmic contractions slow down. For most users, this means feeling full sooner and staying full longer, which is a big part of why the drug works for weight loss.

The trouble starts when slowing down becomes too much slowing down. In gastroparesis, the stomach essentially loses its ability to push food into the small intestine at a normal pace. The result is food sitting in the stomach for hours longer than it should, fermenting, causing waves of nausea and sometimes severe vomiting. A published case report describes a 48-year-old woman with type 2 diabetes who developed persistent nausea and vomiting after resuming semaglutide at a high dose without following the recommended gradual dose increase schedule.² That case is not unique, though it illustrates a specific and avoidable trigger.

How Often Does This Actually Happen?

The short answer is that gastroparesis from semaglutide is uncommon, but it is more common than it is with other weight-loss treatments. A retrospective study comparing semaglutide users to people on bupropion-naltrexone (a different weight-loss drug) found gastroparesis rates of about 6.5 per 1,000 person-years with semaglutide versus 2.1 per 1,000 person-years with bupropion-naltrexone. After adjusting for baseline differences, semaglutide users had roughly three times the risk of developing gastroparesis compared to the bupropion-naltrexone group, and about six times the risk compared to people who had sleeve gastrectomy surgery.³

A separate large cohort study looking more broadly at GLP-1 drugs and severe gastrointestinal motility problems (not just gastroparesis alone but related conditions as well) found that GLP-1 users had a modestly higher rate than people taking a different class of diabetes drugs. Among over 313,000 matched pairs followed for a median of about five months, the rate was roughly 1.0 per 100 person-years for GLP-1 users versus 0.75 for the comparison group, translating to about a 37% higher risk.⁴ So the extra risk is real but not enormous in absolute terms. Most people taking semaglutide will never develop gastroparesis. But the risk is high enough, and the symptoms unpleasant enough, that it deserves attention.

What about milder stomach problems that do not quite meet the threshold for a gastroparesis diagnosis? Those are far more common. In pooled clinical trial data for semaglutide at the 2.4 mg weight-loss dose, about 4% of participants reported severe gastrointestinal side effects like nausea, vomiting, abdominal pain, or diarrhea, compared to under 1% on placebo.⁵ Mild nausea is more common still. There is a spectrum here, from brief queasiness after a meal all the way through to full-blown gastroparesis, and most users experience something closer to the mild end.

What the FDA Safety Databases Show

The FDA’s Adverse Event Reporting System (FAERS) is a database where patients and doctors voluntarily report side effects of drugs. It is not the same as a clinical trial because anyone can file a report, and some drugs get reported more often simply because they are popular and heavily discussed. Even so, the patterns in FAERS data are worth noting. An analysis of the database found that semaglutide was linked to elevated signals for nausea, vomiting, and delayed gastric emptying compared to other drugs in the system.⁶

A larger pharmacovigilance study spanning FAERS data from 2018 through 2025 found that impaired gastric emptying was among the strongest safety signals for GLP-1 drugs as a class, with a reporting odds ratio of about 45 compared to non-GLP-1 drugs. Cyclic vomiting syndrome, a related condition involving repeated episodes of severe vomiting, had an even more dramatic signal, especially for semaglutide.⁷ These numbers sound alarming, but reporting-odds ratios from voluntary databases tend to overstate risk because heavily covered drugs attract disproportionate reporting. They are useful for identifying signals that deserve further study, not for calculating your personal odds of getting gastroparesis.

Dose Escalation Matters More Than You Might Think

One of the clearest risk factors is how fast you ramp up the dose. Semaglutide is prescribed with a gradual titration schedule, starting at a low dose and stepping up every four weeks. This is not just about easing into the drug’s appetite-suppressing effects; it gives your stomach time to adjust to the slower motility. The case report mentioned earlier involved a patient who jumped straight to a high dose after a break from the medication, skipping the stepwise increases entirely. She developed gastroparesis that required hospitalization.²

A systematic review of GLP-1-related gastroparesis cases found that gastrointestinal side effects are especially common during dose escalation phases and that these are the periods when the most serious problems tend to surface.⁸ If you have been off semaglutide for any significant length of time, restarting at the dose you left off is a known risk. The practical lesson is straightforward: follow the prescribed dose schedule. If you stopped and are restarting, go back to the beginning of the ramp-up. This single precaution eliminates what may be the biggest avoidable trigger for gastroparesis on this drug.

Does Gastroparesis From Semaglutide Go Away?

In most documented cases, yes. A systematic review of published cases of GLP-1-induced gastroparesis found that definitive improvement typically followed stopping the drug. Some patients also received prokinetic medications like metoclopramide (a drug that speeds up stomach contractions) and antiemetics while they waited for recovery, but the key intervention was discontinuing semaglutide.⁹ The case report patient who had skipped dose titration recovered after stopping semaglutide and receiving treatment with metoclopramide.²

This is an important distinction from diabetic gastroparesis, which develops over years due to nerve damage and is often irreversible. Drug-induced gastroparesis is generally a functional problem caused by the drug’s ongoing effects on the stomach, not structural damage to the nerves. Remove the drug, and the stomach’s normal motility usually returns. However, semaglutide has a long half-life of about a week, so do not expect symptoms to vanish overnight after stopping. It can take several weeks for the drug to fully clear your system and for gastric motility to normalize.

How Gastroparesis Is Diagnosed

If your doctor suspects gastroparesis, the workup typically involves ruling out a physical blockage first, usually with an upper endoscopy to make sure nothing is mechanically obstructing your stomach or intestines.¹⁰ Once a blockage is excluded, the standard test is a gastric emptying study, considered the gold standard for measuring how quickly your stomach clears food. You eat a meal labeled with a small amount of a radioactive tracer, and a scanner tracks how fast the food leaves your stomach over the next few hours.¹¹

There is an important caveat: high blood sugar by itself can delay gastric emptying. So if you have diabetes, the test results are only meaningful when your glucose is reasonably well controlled at the time of the scan.¹¹ If you are being tested for gastroparesis while on semaglutide, your doctor may want to stop the medication before performing the study to distinguish between “the drug is slowing my stomach” and “my stomach has a lasting motility problem.”

The Surgery Problem

Beyond gastroparesis itself, the gastric-slowing effect of semaglutide creates a real concern for anyone undergoing surgery or procedures that require anesthesia. When you go under general anesthesia, your protective reflexes (like the ability to cough or swallow) are suppressed. If your stomach still has food or liquid in it, that material can come back up and enter your lungs, a potentially life-threatening complication called aspiration. Standard pre-surgery fasting instructions are designed to make sure your stomach is empty, but semaglutide can undermine those instructions by keeping food in the stomach much longer than normal.

Studies confirm the concern. One retrospective analysis found that patients on GLP-1 drugs had retained food in their stomachs about 13% of the time during upper endoscopy, compared to roughly 6% for matched controls, roughly doubling the odds.¹² A prospective study of diabetic patients found the effect was even more pronounced: those on GLP-1 drugs had a median stomach volume nearly four times higher than those not on the drugs, with about 11 times the odds of having what the researchers classified as a full stomach.¹³

A scoping review that pooled data from eight studies found a consistent pattern: residual gastric contents were significantly higher in GLP-1 users across almost all studies, with rates ranging from 19-56% in GLP-1 users versus 5-20% in non-users. However, the review also found that actual aspiration events were not significantly higher. Aspiration rates were around 4.8 per 10,000 in GLP-1 users versus 4.6 per 10,000 in non-users, suggesting that while the risk is theoretically higher, serious harm from it has been rare in the data collected so far.¹⁴

Some anesthesiologists have started using bedside ultrasound to check whether a patient’s stomach is empty before proceeding. A small study of 25 patients who took semaglutide within a week of surgery found that 80% had empty stomachs on ultrasound and went ahead without problems, while the 20% who had retained food had their surgeries rescheduled. Patients who took their dose one to three days before surgery were significantly more likely to have food still in the stomach than those who took it four to six days prior.¹⁵ If you are on semaglutide and have surgery coming up, tell your anesthesiologist. Many surgical guidelines now recommend holding the drug for at least a week before elective procedures.

Are All GLP-1 Drugs Equally Risky?

The various GLP-1 drugs share the same basic mechanism, but the gastroparesis risk does not appear to be identical across all of them. A FAERS analysis found that both semaglutide and liraglutide (Saxenda, Victoza) showed similar safety signals for gastroparesis, with overlapping confidence intervals, while tirzepatide (Mounjaro, Zepbound) did not have any gastroparesis reports in that particular dataset.¹⁶

However, a large propensity-matched analysis of over 800,000 patients told a very different story. That study found tirzepatide users had a strikingly higher incidence of gastroparesis diagnoses at one year compared to semaglutide users: about 0.22% versus 0.002%. The absolute rates are low for both drugs, but the relative difference was nearly 90-fold.¹⁷ These results are surprising and somewhat counterintuitive given the FAERS data, and they may reflect differences in how the drugs were prescribed, the populations using them, or how gastroparesis was documented in different healthcare systems. The researchers noted that rates of gastric emptying studies were nearly identical between the two groups, which makes the gap harder to dismiss as a diagnostic-detection artifact. This is an area where the evidence is still being sorted out, and it would be premature to declare one drug clearly safer than another for stomach motility.

Who Should Be More Cautious

Certain groups face a higher baseline risk of stomach problems on semaglutide. People with diabetes are already at elevated risk for gastroparesis due to nerve damage from chronically high blood sugar, and adding a drug that further slows the stomach can push a borderline situation over the edge. Semaglutide is not recommended for people with a pre-existing gastroparesis diagnosis. If you have diabetes and notice worsening nausea, early fullness, or bloating after starting semaglutide, those symptoms deserve prompt attention rather than being written off as “normal” adjustment.

People who have had prior gastric surgery, those with certain neurological conditions that affect gut motility, and those taking other medications that slow the gut (like opioids or certain antidepressants) may also be at higher risk, though large-scale data on these interactions with semaglutide is limited.

When Treatment Goes Beyond Just Stopping the Drug

The management of GLP-1-related gastroparesis generally starts with stopping the drug and providing supportive care. In hospitalized patients, that often means IV fluids, correcting any electrolyte imbalances from vomiting, and temporarily restricting food by mouth until the stomach starts moving again. Once a patient can eat, the dietary approach shifts toward small, frequent, low-fat meals, because fat slows gastric emptying further.⁹

Prokinetic medications like metoclopramide can help speed up stomach contractions during recovery. Antiemetics help manage nausea. But the systematic review of published cases makes clear that while these medications provide relief, they are not the cure. The definitive improvement comes from stopping semaglutide. For people who still need a weight-loss medication after recovering from gastroparesis, the conversation with their doctor shifts to alternative approaches that do not rely on slowing gastric emptying.

Nutritional Risks That Get Overlooked

Beyond the acute discomfort of gastroparesis, there is a quieter concern about nutrition. Semaglutide causes significant appetite suppression and, in many users, substantial caloric restriction. When gastroparesis or even severe nausea is added to the picture, the combination can lead to inadequate intake of essential nutrients. Research has flagged the potential for nutritional deficiencies among patients on GLP-1 drugs for obesity, especially when the gastrointestinal side effects are severe enough to significantly limit what and how much a person eats.¹⁸ If you are on semaglutide and find yourself eating very little, struggling to keep food down, or losing weight faster than expected, bringing this up with your doctor is worthwhile. Routine monitoring of key nutrient levels is not yet standard practice for people on these drugs, but there is a case to be made that it should be, especially in patients experiencing persistent stomach symptoms.